scholarly journals Neuroendocrine Differentiation in Breast Cancer: Clinicopathological Significance of Bcl-2 Positive Solid Papillary Carcinoma

2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Yoichiro Okubo ◽  
Takuji Okubo ◽  
Yoshimi Okubo ◽  
Takao Ishiwatari
Keyword(s):  
Breast Cancer ◽  
Papillary Carcinoma ◽  
Neuroendocrine Tumors ◽  
Ductal Carcinoma ◽  
Neuroendocrine Differentiation ◽  
Prognostic Indicator ◽  
Low Grade ◽  
Term Survival ◽  
Solid Papillary Carcinoma ◽  
Poor Prognostic Indicator

Solid papillary carcinoma (SPC) is considered a rare malignant breast tumor. Maluf and Koerner first reported this disease entity as a special type of ductal carcinoma in situ with several characteristic histopathological features, including low-grade cellular atypia, intracellular or extracellular mucin deposition, and solid papillary growth pattern, as well as neuroendocrine differentiation. The present paper describes a case of SPC with bcl-2 expression, which is known as a marker for malignancy of neuroendocrine tumors. Interestingly, despite bcl-2 expression being a poor prognostic indicator of neuroendocrine tumors, the patient with this tumor has achieved long-term survival (approximately 6 years) at the time of writing this report. Because previous investigators reported that bcl-2 expression might play a role in the inhibition of the development of breast cancer, we suggest that bcl-2 expression might reflect a good prognosis in patients with SPC, rather than being a poor prognostic indicator, as it is in several types of neuroendocrine tumor. However, to confirm this hypothesis, further investigation is required.

Invasive Solid Papillary Carcinoma of the Nipple With Pagetoid Extension and Nodal Metastasis

2018 ◽  
Vol 26 (6) ◽  
pp. 573-577 ◽  
Author(s):  
Hideharu Domoto ◽  
Akiko Watanabe ◽  
Michio Sakata ◽  
Akihiko Shimada ◽  
Kiyoshi Mukai
Keyword(s):  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Tumor Cell ◽  
Papillary Carcinoma ◽  
Neuroendocrine Differentiation ◽  
Low Grade ◽  
Axillary Lymph ◽  
Node Metastasis ◽  
Solid Papillary Carcinoma ◽  
Eosinophilic Cytoplasm

We report a case of invasive solid papillary carcinoma (SPC) of the nipple with Pagetoid extension to the skin and lymph node metastasis. SPC is an uncommon primary breast cancer accounting for less than 1% of all breast cancers. Only 2 cases occurring in the nipple have been reported. However, both cases were without Pagetoid extension or lymph node metastasis. The presently reported tumor consisted of irregularly shaped solid cell nests with delicate fibrovascular cores. The tumor cells had round nuclei with low-grade atypia and eosinophilic cytoplasm. Neuroendocrine differentiation was confirmed by immunohistochemical positivity for CD56, synaptophysin, and chromogranin A. Immunohistochemistry also confirmed the absence of myoepithelial cells around the tumor cell nests. Therefore, a diagnosis of invasive SPC was made. Additionally, tumor cell deposits in the intramammary and axillary lymph nodes were identified, and these deposits had the same histological characteristics as the invasive SPC of the nipple. The invasiveness of SPC can be difficult to determine. However, the tumor cell nests in the current case exhibited a retraction artifact, which is known to be associated with invasive carcinoma and a poor prognosis, as well as morphological patterns that have been previously identified as characteristic of invasive SPC. Although SPC is widely recognized as having a favorable outcome, the existence of exceptionally aggressive cases occurring in the nipple must be recognized. Additional cases of invasive SPC of the nipple are needed to analyze the clinicopathological correlation.

scholarly journals EP.TH.3Male Breast Cancer: A Series of Three Extremely Rare Cases

2021 ◽  
Vol 108 (Supplement_7) ◽  
Author(s):  
Ahmed Latif ◽  
Amna Suliman ◽  
Anupama Nagarajakumar ◽  
Mihir Khan ◽  
Anna Metafa ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Papillary Carcinoma ◽  
Ductal Carcinoma ◽  
Case Series ◽  
Mucinous Carcinoma ◽  
Wall Thickening ◽  
Low Grade ◽  
Breast Cancers ◽  
History Of ◽  
One Year

Abstract Aims Male breast cancer (MBC) is rare and accounts for 1% of all breast cancers. We present a case series of three very rare histological subtype MBC within one year in a UK hospital. Methods We retrospectively identified all MBCs from the local breast cancer database. Their presentations, radiology and histopathology were analysed. Results Three MBCs were identified from 2019 to 2020. A healthy 28-year-old presented with a right breast lump. Ultrasound (USS) revealed a partially cystic 15mm U3 lesion. Mammography (MMG) was suggestive of gynaecomastia (M2). Biopsy was inconclusive. Diagnostic excision revealed Papillary Ductal Carcinoma in Situ (DCIS) with involved margin. Mastectomy and Sentinel Node Biopsy (SNB) confirmed low-grade Papillary DCIS. A 48-year-old with background of hyperlipidaemia presented with a 2-year history of left axillary lump. PET CT demonstrated an FDG-avid lesion. USS showed a superficial U3 28mm lesion. MMG showed a 34mm density (M4). Biopsy identified Mucinous Carcinoma. Wide Local Excision and SNB confirmed grade 2 Mucinous Carcinoma. A 75-year-old with history of cardiac disease, COPD and Type 2 Diabetes, presented with a right retro-areolar lump. MMG identified a 47mm mass (M4). USS showed a 41mm cystic lesion with wall thickening (U4). Cytology was inconclusive. Biopsy identified intra-cystic papillary carcinoma. Mastectomy and SNB confirmed intra-cystic papillary carcinoma. All three histological subtypes are extremely rare and account for less than 4% of all MBCs. Conclusions MBC is rare but increasing in incidence. More research and awareness are needed to minimise delays in diagnosis and treatment even in young men.

scholarly journals Invasive solid papillary carcinoma with neuroendocrine differentiation of the breast: a case report and literature review

2020 ◽  
Vol 6 (1) ◽  
Author(s):  
Xue Lin ◽  
Yoshiaki Matsumoto ◽  
Tomomi Nakakimura ◽  
Kazuo Ono ◽  
Shigeaki Umeoka ◽  
...  
Keyword(s):  
Case Report ◽  
Literature Review ◽  
Papillary Carcinoma ◽  
Neuroendocrine Differentiation ◽  
Solid Papillary Carcinoma

scholarly journals Encapsulated Papillary Carcinoma of the Breast: Imaging Features with Histopathologic Correlation

2020 ◽  
Vol 2 (6) ◽  
pp. 590-597
Author(s):  
Sarah E Bonnet ◽  
Gloria J Carter ◽  
Wendie A Berg
Keyword(s):  
Papillary Carcinoma ◽  
Core Needle Biopsy ◽  
Needle Biopsy ◽  
Breast Imaging ◽  
Ductal Carcinoma ◽  
Imaging Features ◽  
Term Survival ◽  
Core Needle ◽  
Cystic Component

Abstract Encapsulated papillary carcinoma (EPC) is a rare, clinically indolent breast malignancy most common in postmenopausal women. Absence of myoepithelial cells at the periphery is a characteristic feature. Mammographically, EPC typically presents as a mostly circumscribed, noncalcified, dense mass that can have focally indistinct margins when there is associated frank invasive carcinoma. Ultrasound shows a circumscribed solid or complex cystic and solid mass, and occasional hemorrhage in the cystic component may produce a fluid-debris level; the solid components typically show intense washout enhancement on MRI. Color Doppler may demonstrate a prominent vascular pedicle and blood flow within solid papillary fronds. Encapsulated papillary carcinoma can exist in pure form; however, EPC is often associated with conventional ductal carcinoma in-situ and/or invasive ductal carcinoma, no special type. Adjacent in-situ and invasive disease may be only focally present at the periphery of EPC and potentially unsampled at core-needle biopsy. In order to facilitate diagnosis, the mass wall should be included on core-needle biopsy, which will show absence of myoepithelial markers. Staging and prognosis are determined by any associated frankly invasive component, with usually excellent long-term survival and rare distant metastases.

scholarly journals PERFORMANCE ANALYSIS OF BREAST CANCER CLASSIFICATION USING DECISION TREE CLASSIFIERS

2017 ◽  
Vol 9 (2) ◽  
pp. 19 ◽  
Author(s):  
P. Hamsagayathri ◽  
P. Sampath
Keyword(s):  
Breast Cancer ◽  
Decision Tree ◽  
Ductal Carcinoma ◽  
Research Work ◽  
The United States ◽  
Breast Cancer Dataset ◽  
Decision Tree Classifier ◽  
Cancer Dataset ◽  
Term Survival ◽  
Tree Classifier

Breast cancer is one of the dangerous cancers among world’s women above 35 y. The breast is made up of lobules that secrete milk and thin milk ducts to carry milk from lobules to the nipple. Breast cancer mostly occurs either in lobules or in milk ducts. The most common type of breast cancer is ductal carcinoma where it starts from ducts and spreads across the lobules and surrounding tissues. According to the medical survey, each year there are about 125.0 per 100,000 new cases of breast cancer are diagnosed and 21.5 per 100,000 women due to this disease in the United States. Also, 246,660 new cases of women with cancer are estimated for the year 2016. Early diagnosis of breast cancer is a key factor for long-term survival of cancer patients. Classification plays an important role in breast cancer detection and used by researchers to analyse and classify the medical data. In this research work, priority-based decision tree classifier algorithm has been implemented for Wisconsin Breast cancer dataset. This paper analyzes the different decision tree classifier algorithms for Wisconsin original, diagnostic and prognostic dataset using WEKA software. The performance of the classifiers are evaluated against the parameters like accuracy, Kappa statistic, Entropy, RMSE, TP Rate, FP Rate, Precision, Recall, F-Measure, ROC, Specificity, Sensitivity.

Histological Assessment of Breast Lesions Identified Exclusively by Magnetic Resonance

2014 ◽  
Vol 80 (10) ◽  
pp. 944-947
Author(s):  
Victoria O'connor ◽  
Elizabeth Arena ◽  
Joslyn Albright ◽  
Nefertiti Brown ◽  
Ryan O'connor ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Magnetic Resonance ◽  
Breast Biopsy ◽  
Ductal Carcinoma ◽  
Low Grade ◽  
Breast Lesions ◽  
Significant Family History ◽  
Ductal Hyperplasia ◽  
Significant Pathology

Radiologic–pathologic correlation of lesions diagnosed by magnetic resonance (MR) is precluded by insufficient data on histological characteristics of lesions suspicious on MR but not visible on concurrent mammogram or ultrasound. The objective of this study was to describe histological features of breast lesions diagnosed exclusively by MR. The participants underwent MR-guided breast biopsy between 2007 and 2012 for a suspicious lesion not identified by mammography or ultrasound. Histology slides were interpreted retrospectively by a breast pathologist. Of 126 patients (126 lesions), 34 (27%) had new breast cancer, 51 (40.5%) previous breast cancer, and 41 (32.5%) dense breasts or a significant family history of breast cancer. MR identified 23 (18.3%) invasive cancers: 20 were Grade 1 and 17 were ductal. Of the 126 lesions, 16 (13%) were ductal carcinoma in situ (DCIS), four were atypical ductal hyperplasia and atypical lobular hyperplasia (3%), and 68 (54%) were benign. Fifteen biopsies (12%) had no significant pathology. Five DCIS lesions were upgraded to T1 invasive cancers. Approximately 30 per cent of suspicious lesions detected exclusively by MR are invasive or in situ cancers that are predominantly low grade. Further studies are needed to determine if malignant lesions can be prospectively distinguished by MR characteristics.

Immunotherapy of Advanced Breast Cancer With a Heterophilic Ganglioside (NeuGcGM3) Cancer Vaccine

2003 ◽  
Vol 21 (6) ◽  
pp. 1015-1021 ◽  
Author(s):  
Adriana Carr ◽  
Edmundo Rodríguez ◽  
María del Carmen Arango ◽  
Rolando Camacho ◽  
Marta Osorio ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Vaccine ◽  
Ductal Carcinoma ◽  
Serum Antibody ◽  
World Health ◽  
Stage Iii ◽  
Induction Phase ◽  
Low Grade ◽  
Breast Cancer Patients ◽  
Monthly Basis

Purpose: A heterophilic ganglioside cancer vaccine was developed by combining NeuGcGM3 with the outer membrane protein complex of Neisseria meningitidis to form very small size proteoliposomes (VSSP). A phase I clinical trial was performed to determine safety and immunogenicity of this vaccine. Patients and Methods: Stage III to IV breast cancer patients received up to 15 (200 μg) doses of the vaccine by intramuscular injection. The first five doses (induction phase) were given at 2-week intervals, with the remaining treatment (maintenance) administered on a monthly basis. Results: Twenty-one patients, 11 of whom had metastatic disease, were included. Main toxicities included erythema and induration at the injection site, sometimes associated with mild pain, and low-grade fever (World Health Organization grades 1 and 2). All treated patients who completed the induction phase developed anti-NeuGcGM3 antibody titers between 1:1,280 and 1:164,000 immunoglobulin G (IgG), and 1:640 and 1:164,000 IgM. Noteworthy specific IgA antibodies were induced by vaccination in all stage III patients and in three stage IV patients. Serum antibody levels were higher in the stage III patients, with the larger increases observed after week 32. The antiganglioside IgG subclasses were mainly IgG1 and IgG3. Hyperimmune sera increased complement-mediated cytotoxicity versus P3X63 myeloma cells and a marked IgG differential reactivity against human mammary ductal carcinoma samples. Conclusion: NeuGcGM3/VSSP/Montanide ISA 51 is an unusual immunogenic ganglioside vaccine and also seems to be safe in this small trial. Immunologic surrogates of activity indicate that this reagent warrants further investigation.

scholarly journals Subclonal analysis in a lobular breast cancer with classical and solid growth pattern mimicking a solid-papillary carcinoma

2017 ◽  
Vol 3 (3) ◽  
pp. 191-202 ◽  
Author(s):  
Matthias Christgen ◽  
Stephan Bartels ◽  
Jana Lisa van Luttikhuizen ◽  
Maximilian Schieck ◽  
Stefanie Pertschy ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Papillary Carcinoma ◽  
Growth Pattern ◽  
Lobular Breast Cancer ◽  
Solid Papillary Carcinoma

Does receptor status impact survival of patients with mid-gut neuroendocrine tumors?

2016 ◽  
Vol 34 (4_suppl) ◽  
pp. 227-227 ◽  
Author(s):  
Yi-Zarn Wang ◽  
David T Beyer
Keyword(s):  
Breast Cancer ◽  
Cancer Treatment ◽  
Neuroendocrine Tumors ◽  
Statistical Significance ◽  
Somatostatin Receptors ◽  
Breast Cancer Treatment ◽  
Mibg Imaging ◽  
Term Survival ◽  
Receptor Status ◽  
Imaging Results

227 Background: Neuroendocrine tumors (NETs) are rare neoplasms increasing in incidence due to greater awareness among patients and physicians. The most reliable diagnostic imaging study has been the 111In-pentetreotide scan which binds to somatostatin receptors of the tumor. It is known that breast cancer treatment outcome is tightly correlated with degree of tumor cell differentiation and receptor status. We hypothesize that receptor status determined by 111In-pentetreotide (Octreoscan) and 123I-Metaiodobenzylguanidine (MIBG) imaging results can predict prognosis for small bowel NETs. Methods: A database with all patients seen at the LSU/Ochsner NET Program was queried for nuclear medicine scan results. Included patients had a histologically confirmed ileal, jejunal, or small intestinal NET and Octreoscan and MIBG imaging results. Kaplan-Meier survival analysis was performed and statistical significance was determined by Log-rank test (p<0.05). Results: 110 patients diagnosed between July 1994 and September 2013 were included. There were 64 females (64/110, 58%) and 46 males (46/110, 42%). Seventy-three (73/110, 66%) and sixty-three (63/100, 57%) patients had positive Octreoscan and MIBG imaging results, respectively. 5- and 10-year survival was calculated and sorted into four groups based on imaging positivity. Conclusions: Most midgut NETs present with positive Octreoscans which reflect positive receptor status; a favorable feature in prognosis based on the well-established breast cancer treatment experience. Unexpectedly, our data have shown receptor scintigraphy studies result has no baring in short term survival. More surprisingly, patients with double positive scan demonstrate a substantial survival disadvantage over a longer interval. Further longitudinal studies are required to determine if NET receptor status can reliably predict patient prognosis and the mystery of the reversal relation of the receptor status of NET patients and their prognosis. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document